Table 2.
Distribution of secondary outcomes and potential confounders in children with and without Fetal Inflammatory Response Syndrome (FIRS).
| FIRS percent (N) | Control percent (N) | χ2 | p | Odds ratio | Odds ratio CI | |
|---|---|---|---|---|---|---|
| Medications | N = 1717 | N =10915 | ||||
| Anti-inflammatory medications | 49.6% (852) | 47.3% (5168) | 2.98 | 0.084 | 1.10 | (0.99, 1.21) |
| Anti-infection medications | 83.9% (1440) | 84.7% (9243) | 0.69 | 0.405 | 0.94 | (0.82, 1.08) |
| Maternal history of psychiatric diseases | N = 1631 | N = 12414 | ||||
| Any psychiatric disorder in mother | 63.4% (1034) | 62.1% (7713) | 0.93 | 0.335 | 1.06 | (0.95, 1.17) |
| Mother had suicide attempt | 1.7% (28) | 1.2% (147) | 2.9 | 0.088 | 1.46 | (0.97, 2.19) |
| In utero exposure to substances | N = 2042 | N = 12931 | ||||
| Alcohol exposure in utero | 1.3% (27) | 0.8% (101) | 5.47 | 0.019 | 1.70 | (1.11, 2.61) |
| Amphetamine exposure in utero | 1.6% (32) | 1.2% (158) | 1.41 | 0.235 | 1.29 | (0.88, 1.89) |
| Cannabis exposure in utero | 6.3% (128) | 4.1% (534) | 18.6 | <0.001 | 1.55 | (1.27, 1.89) |
| Cocaine exposure in utero | 1.4% (29) | 1.1% (137) | 1.78 | 0.183 | 1.35 | (0.90, 2.01) |
| Hallucinogen exposure in utero | 0.0% (1) | 0.0% (2) | 0.02 | 0.878 | 3.17 | (0.29, 34.95) |
| Nicotine exposure in utero | 12.4% (254) | 10.4% (1342) | 7.65 | 0.006 | 1.23 | (1.06, 1.42) |
| Opioid exposure in utero | 4.8% (99) | 3.9% (506) | 3.74 | 0.053 | 1.25 | (1.00, 1.56) |
| Sedative exposure in utero | 0.7% (14) | 0.8% (101) | 0.1 | 0.747 | 0.88 | (0.50, 1.54) |
| Any substance exposure in utero | 12.1% (248) | 9.0% (1168) | 19.59 | <0.001 | 1.39 | (1.20, 1.61) |
| Neonatal substance use diagnosis | N = 1641 | N = 12492 | ||||
| Neonatal substance use diagnosis | 18.6% (305) | 12.2% (1526) | 51.6 | <0.001 | 1.64 | (1.43, 1.88) |
| Demographics | N = 2055 | N = 13022 | ||||
| Year of birth | 2010.6 + /−1.8 | 2010.8 + /−1.8 | t = −4.49 | <0.001 |